DEGENRX
Biopharmaceutical company developing novel therapeutic solutions to treat neurodegenerative diseases
DEGENRX
Social Links:
Industry:
Biotechnology Pharmaceutical
Founded:
2018-10-19
Address:
Tilburg, Noord-Brabant, The Netherlands
Country:
The Netherlands
Website Url:
http://www.degenrx.com
Total Employee:
1+
Status:
Active
Total Funding:
0
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default WordPress Sitelinks Search Box Microsoft Exchange Online Organization Schema Office 365 Mail IPv6
Similar Organizations
BioCorteX
BioCorteX is a pharmaceutical company specializing in enhanced therapeutics to cure neurodegenerative diseases using microorganisms.
Hunter-Fleming Ltd
Hunter-Fleming Ltd is a biopharmaceutical company developing new medicines to treat neurodegenerative and inflammatory disorders.
Neurophoenix
Neurophoenix is a biopharmaceutical company developing a new therapeutic solution for optic neuropathies.
Oxyrane UK
Oxyrane UK is a biopharmaceutical company developing biosuperior enzyme replacement therapies to treat inherited diseases.
Pharmasum Therapeutics
A pharmaceutical company developing drugs for autoimmune/metabolic and neurological diseases
PledPharma
PledPharma is a Swedish pharmaceutical company developing new therapies for life-threatening diseases.
Investors List
BOM Brabant Ventures
BOM Brabant Ventures investment in Series A - DegenRx
Official Site Inspections
http://www.degenrx.com Semrush global rank: 5.64 M Semrush visits lastest month: 1.49 K
- Host name: w98.rzone.de
- IP address: 81.169.145.152
- Location: Berlin Germany
- Latitude: 52.5174
- Longitude: 13.3985
- Timezone: Europe/Berlin
- Postal: 12529
More informations about "DegenRx"
DegenRx | A biotech company developing AAV-mediated gene …
DegenRx is a biotech company developing AAV-mediated gene therapy for the treatment of CNS diseases such as Alzheimer’s and Parkinson’s disease. Using Adeno-Associated-Viral (AAV) …See details»
DegenRx B.V. - Crunchbase Company Profile & Funding
DegenRx is a biotech startup working on AAV-mediated gene therapy for CNS disorders like Parkinson's and Alzheimer's. They transmit genes to the brain …See details»
About us | DegenRx
Life Sciences & Health grant for gene therapy partnership between the Amsterdam Center for Neurogenomics & Cognitive Research and DegenRx; DegenRx selected for GES 2019; …See details»
DegenRx 2025 Company Profile: Valuation, Funding & Investors
DegenRx General Information Description. Operator of a gene therapy company intended to find and develop treatments for neurodegenerative diseases. The company uses adeno …See details»
DegenRx B.V. - Funding, Financials, Valuation & Investors
DegenRx is a biopharmaceutical company that develops therapeutic solutions to treat neurodegenerative diseases. New. Resources. Advanced Search. Start Free Trial . ... How …See details»
DegenRx - VentureRadar
DegenRx is a biotech company developing AAV-mediated gene therapy for the treatment of CNS diseases such as Alzheimer’s and Parkinson’s disease. Using Adeno-Associated-Viral (AAV) …See details»
DegenRx - 2025 Company Profile, Funding & Competitors - Tracxn
Mar 23, 2025 DegenRx - Developer of antibody-based gene therapy for neurodegenerative diseases. Raised funding over 1 round from 2 investors. DegenRx has 3438 competitors.See details»
DegenRx Company Profile - Office Locations, Competitors ... - Craft
DegenRx is a biotech company developing AAV-mediated gene therapy for the treatment of CNS diseases such as Alzheimer’s and Parkinson’s disease. It uses Adeno-Associated-Viral (AAV) …See details»
DegenRx B.V. - Tech Stack, Apps, Patents & Trademarks
DegenRx is a biopharmaceutical company that develops therapeutic solutions to treat neurodegenerative diseases.See details»
DegenRx - Products, Competitors, Financials, Employees, …
DegenRx operates as a biotech company focused on developing gene therapy for neurodegenerative diseases. Use the CB Insights Platform to explore DegenRx's full profile. …See details»
DegenRx B.V. - LinkedIn
DegenRx is a biotech company developing AAV-mediated gene therapy for the treatment of Alzheimer’s disease. Using Adeno-Associated-Viral (AAV) vectors we deliver genes in the brain that initiate ...See details»
Introduction - DegenRx
It is DegenRx’ mission to find and develop cures for neurodegenerative disease in order to stay longer healthier when we get older. Antibodies are our immune system’s response to many …See details»
DegenRx secures funding for Alzheimer’s disease gene therapy
Dec 21, 2018 DegenRx, a biopharmaceutical company developing novel therapeutic solutions to treat neurodegenerative diseases, has secured financing for their antibody-based gene …See details»
Team - DegenRx
Interim Chief Executive Officer Inez de Greef-van der Sandt is a pharmaceutical professional and entrepreneur with extensive experience within the pharma and biotech industry. In 2010, she …See details»
Life Sciences & Health grant for gene therapy partnership …
Jun 4, 2019 Center for Neurogenomics & Cognitive Research (CNCR) and DegenRx have been awarded a grant from the Top Sector Life Sciences & Health (Health~Holland) for their joint …See details»
DegenRx B.V. - Crunchbase
DegenRx is a biopharmaceutical company that develops therapeutic solutions to treat neurodegenerative diseases.See details»
AAVmediatedgenetherapyaslocaltreatmentmodality ...
Title: AAV mediated gene therapy as local treatment modality directed against amyloid beta oligomers in the brain using a high affinity, high specificity antibodySee details»
DegenRx B.V. - Contacts, Employees, Board Members
DegenRx is a biopharmaceutical company that develops therapeutic solutions to treat neurodegenerative diseases. New. Resources. Advanced Search. Start Free Trial . Talk With …See details»
Alzheimer’s disease - DegenRx
Introduction Alzheimer’s disease is affecting about two-thirds of the 50 million people that are reported to suffer from dementia worldwide. Other than symptomatic treatment, there is no …See details»
Dengvaxia® Vaccine Overview and Updates | Sanofi
World Health Organization (WHO). Revised SAGE recommendation on use of dengue vaccine. April 2018. WER9323-329-343.pdf (who.int). Last accessed December 2023; Sanofi press …See details»